PSMB11
ENSG00000222028
Target class
Enzyme
Chromosome
14
Approved drugs
3
Clinical candidates (approved and in development)
6
- Approved drugs
- 3
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Other names
- beta5t
- Target name
- PSMB11
- Gene name
- Proteasome subunit beta 11
- Gene symbol
- PSMB11
- Protein name
- Proteasome subunit beta type-11 (EC 3.4.25.1) (Proteasome subunit beta-5t)
- Gene biotype
- Protein coding
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 0
- Highest tissue expression
- 0.75
- Tissue specificity (Gini)
- 0.917
- Tissue specificity (tau)
- 0.994
- KEGG gene identifiers
- hsa:122706
- Reactome pathways
- R-HSA-9907900
- Protein interaction confidence
- 0.845156
- Protein interaction partners
- 32
- End position
- 23044060
- Start position
- 23042212
- Chromosome
- 14
- Strand
- Forward
- Cytoplasm . Nucleus .
- Tissue specificity (tau)
- 0.993711
- Expression inequality (Gini)
- 0.917407
Expression in transcripts per million
- Testis
- 0.75
- Nerve - Tibial
- 0.03
- Brain - Hypothalamus
- 0.02
- Brain - Spinal cord (cervical c-1)
- 0.02
- Brain - Hippocampus
- 0.02
Expression in transcripts per million
- Testis0.75
- Nerve - Tibial0.03
- Brain - Hypothalamus0.02
- Brain - Spinal cord (cervical c-1)0.02
- Brain - Hippocampus0.02
- Brain - Nucleus accumbens (basal ganglia)0.02
- Brain - Substantia nigra0.02
- Muscle - Skeletal0.02
- Brain - Caudate (basal ganglia)0.02
- Brain - Putamen (basal ganglia)0.01
- Skin - Sun Exposed (Lower leg)0.01
- Brain - Amygdala0.01
- Heart - Atrial Appendage0.01
- Brain - Cortex0.01
- Brain - Anterior cingulate cortex (BA24)0.01
- Heart - Left Ventricle0.01
- Kidney - Medulla0.01
- Breast - Mammary Tissue0
- Brain - Cerebellum0
- Skin - Not Sun Exposed (Suprapubic)0
- Artery - Coronary0
- Cervix - Ectocervix0
- Esophagus - Gastroesophageal Junction0
- Esophagus - Mucosa0
- Vagina0
And 29 more, listed on the interactive page.
Biological processes
- GO:0006508
Cellular components
- GO:0005829
- GO:0005515
- GO:0008233
Related records
Trials (799)
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- 3D PET Myocardial Blood Flow and Rb82 Infusion Profiles
- 4SCAR-T Therapy Post CD19-targeted Immunotherapy
- A Basket Study of CTA313 in Participants With Active Autoimmune Diseases
- A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors
- A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment
- A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer
- A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus
- A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors
- A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer
- A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
- A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion
- A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer
- A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."
- A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II
- A Multi-site Study of Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy
Drugs (6)
- Bortezomib D-mannitol 26S proteasome inhibitor
- Carfilzomib 26S proteasome inhibitor
- Ixazomib 26S proteasome inhibitor
- Ixazomib citrate 26S proteasome inhibitor
- Marizomib 20S proteasome inhibitor
- Oprozomib 26S proteasome inhibitor